| PTO Form 1553 (Rev 9/2005) |
| OMB No. 0651-0054 (Exp. 10/31/2017) |
Trademark/Service Mark Request to Divide
The table below presents the data as entered.
Input Field
|
Entered
|
| SERIAL NUMBER |
85442528 |
| LAW OFFICE ASSIGNED |
LAW OFFICE 116 |
| EXTENSION OF USE |
YES |
| MARK SECTION |
| MARK |
CERULEAN |
| REQUEST TO DIVIDE |
YES |
| GOOD(S)/SERVICE(S) IN USE |
pharmaceutical preparations for use in the treatment of oncological diseases or disorders, including malignant cancers or neoplasms; pharmaceutical
preparations for use in chemotherapy; pharmaceutical preparations for use in the treatment of oncological diseases or disorders, including malignant cancers or neoplasms, all containing nanometer
size compounds which facilitate targeting or delivery of the active ingredient; pharmaceutical preparations for use in chemotherapy, containing nanometer size compounds which facilitate targeting or
delivery of the active ingredient |
| GOOD(S)/SERVICES INTENT TO USE |
pharmaceutical preparations for use in the diagnosis, prognosis or prevention of oncological diseases or disorders, including malignant cancers or
neoplasms; pharmaceutical preparations for use in the diagnosis, prognosis, prevention or treatment of oncological diseases or disorders, including pre-cancerous diseases or disorders and benign
cancers or neoplasms, inflammation and inflammatory diseases or disorders, and cardiovascular diseases or disorders; pharmaceutical preparations for use in modulating angiogenesis; pharmaceutical
preparations for use in the diagnosis, prognosis and prevention of oncological diseases or disorders, including malignant cancers or neoplasms, all containing nanometer size compounds which
facilitate targeting or delivery of the active ingredient; pharmaceutical preparations for use in the diagnosis, prognosis, prevention or treatment of oncological diseases or disorders, including
pre-cancerous diseases or disorders and benign cancers or neoplasms, inflammation and inflammatory diseases or disorders, and cardiovascular diseases or disorders, all containing nanometer size
compounds which facilitate targeting or delivery of the active ingredient; pharmaceutical preparations for use in modulating angiogenesis, containing nanometer size compounds which facilitate
targeting or delivery of the active ingredient |
| SIGNATURE SECTION |
| ORIGINAL PDF FILE |
hw_6547140130-124348319_._CERULEAN_-_Signed_Allegation_of_Use__F1053148_.PDF |
CONVERTED PDF FILE(S)
(2 pages) |
\\TICRS\EXPORT16\IMAGEOUT16\854\425\85442528\xml2\RTD0002.JPG |
| |
\\TICRS\EXPORT16\IMAGEOUT16\854\425\85442528\xml2\RTD0003.JPG |
| SIGNATORY'S NAME |
Jean M. Silveri |
| SIGNATORY'S POSITION |
General Counsel |
| REQUEST TO DIVIDE SIGNATURE |
/ac for de/ |
| SIGNATORY'S NAME |
David Ehrlich |
| SIGNATORY'S POSITION |
Attorney of record, New York bar member |
| DATE SIGNED |
07/24/2012 |
| AUTHORIZED SIGNATORY |
YES |
| PAYMENT SECTION |
| NUMBER OF CLASSES IN USE |
1 |
| SUBTOTAL AMOUNT [ALLEGATION OF USE FEE] |
100 |
| REQUEST TO DIVIDE FEE |
100 |
| NUMBER OF CLASSES REQUIRING NEW APPLICATION FEE |
1 |
| SUBTOTAL AMOUNT [NEW APPLICATION FEE] |
325 |
| TOTAL AMOUNT |
525 |
| PAYMENT METHOD |
DA |
| FILING INFORMATION |
| SUBMIT DATE |
Tue Jul 24 12:57:36 EDT 2012 |
| TEAS STAMP |
USPTO/SOU-XX.XX.XXX.XXX-2
0120724125736872945-85442
528-490135bbdcfff3a516c1d
992d4f17714486-DA-12914-2
0120724124348319820 |
| PTO Form 1553 (Rev 9/2005) |
| OMB No. 0651-0054 (Exp. 10/31/2017) |
Trademark/Service Mark Request to Divide
To the Commissioner for Trademarks:
MARK: CERULEAN
SERIAL NUMBER: 85442528
REQUEST TO DIVIDE
The applicant is requesting to divide the application and specifies the following:
The following good(s) or service(s) is/are now in use: pharmaceutical preparations for use in the treatment of oncological diseases or disorders, including malignant cancers or neoplasms;
pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for use in the treatment of oncological diseases or disorders, including malignant cancers or neoplasms, all
containing nanometer size compounds which facilitate targeting or delivery of the active ingredient; pharmaceutical preparations for use in chemotherapy, containing nanometer size compounds which
facilitate targeting or delivery of the active ingredient
The following good(s) or service(s) remain(s) under the Section 1(b), intent to use basis: pharmaceutical preparations for use in the diagnosis, prognosis or prevention of oncological diseases or
disorders, including malignant cancers or neoplasms; pharmaceutical preparations for use in the diagnosis, prognosis, prevention or treatment of oncological diseases or disorders, including
pre-cancerous diseases or disorders and benign cancers or neoplasms, inflammation and inflammatory diseases or disorders, and cardiovascular diseases or disorders; pharmaceutical preparations for use
in modulating angiogenesis; pharmaceutical preparations for use in the diagnosis, prognosis and prevention of oncological diseases or disorders, including malignant cancers or neoplasms, all
containing nanometer size compounds which facilitate targeting or delivery of the active ingredient; pharmaceutical preparations for use in the diagnosis, prognosis, prevention or treatment of
oncological diseases or disorders, including pre-cancerous diseases or disorders and benign cancers or neoplasms, inflammation and inflammatory diseases or disorders, and cardiovascular diseases or
disorders, all containing nanometer size compounds which facilitate targeting or delivery of the active ingredient; pharmaceutical preparations for use in modulating angiogenesis, containing
nanometer size compounds which facilitate targeting or delivery of the active ingredient
A fee payment in the amount of $100 will be submitted with the form, representing payment for the allegation of use for 1 class.
A fee payment in the amount of $100 will be submitted with the form, representing payment for the request to divide fee.
A fee payment in the amount of $325 will be submitted with the form, representing payment for the new application fee for 1 class.
Declaration
The attached signature image file:
Original PDF file:
hw_6547140130-124348319_._CERULEAN_-_Signed_Allegation_of_Use__F1053148_.PDF
Converted PDF file(s) (2 pages)
Signature File1
Signature File2
Signatory's Name: Jean M. Silveri
Signatory's Position: General Counsel
Request to Divide Signature:
Signature: /ac for de/ Date Signed: 07/24/2012
Signatory's Name: David Ehrlich
Signatory's Position: Attorney of record, New York bar member
The signatory has confirmed that he/she is an attorney who is a member in good standing of the bar of the highest court of a U.S. state, which includes the District of Columbia, Puerto Rico, and
other federal territories and possessions; and he/she is currently the applicant's attorney or an associate thereof; and to the best of his/her knowledge, if prior to his/her appointment another U.S.
attorney or a Canadian attorney/agent not currently associated with his/her company/firm previously represented the applicant in this matter: (1) the applicant has filed or is concurrently filing a
signed revocation of or substitute power of attorney with the USPTO; (2) the USPTO has granted the request of the prior representative to withdraw; (3) the applicant has filed a power of attorney
appointing him/her in this matter; or (4) the applicant's appointed U.S. attorney or Canadian attorney/agent has filed a power of attorney appointing him/her as an associate attorney in this
matter.
Serial Number: 85442528
Internet Transmission Date: Tue Jul 24 12:57:36 EDT 2012
TEAS Stamp: USPTO/SOU-XX.XX.XXX.XXX-2012072412573687
2945-85442528-490135bbdcfff3a516c1d992d4
f17714486-DA-12914-20120724124348319820
